Representative Publications

1. Hu J, Tan P, Ishihara M, Bayley NA, Schokrpur S, Reynoso JG, Zhang Y, Lim RJ, Dumitras C, Yang L, Dubinett SM, Jat PS, Van Snick J, Huang J, Chin AI, Prins RM, Graeber TG, Xu H*, Wu L*. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. Signal Transduct Target Ther. 2023 Apr 17;8(1):155. doi: 10.1038/s41392-023-01362-2. PMID: 37069149; PMCID: PMC10110583.

2. Liu H, Duan C, Yang X, Liu J, Deng Y, Tiselius HG, Ye Z, Wang T, Xing J, Xu H*. Metformin suppresses calcium oxalate crystal-induced kidney injury by promoting Sirt1 and M2 macrophage-mediated anti-inflammatory activation. Signal Transduct Target Ther. 2023 Jan 27;8(1):38. doi: 10.1038/s41392-022-01232-3. PMID: 36702833; PMCID: PMC9879973.

3. Mao X, Wang G, Wang Z, Duan C, Wu X, Xu H*. Theranostic Lipid Nanoparticles for Renal Cell Carcinoma. Adv Mater. 2023 Sep 25:e2306246. doi: 10.1002/adma.202306246. Epub ahead of print. PMID: 37747365.

4. Zhang Y, Yao X, Zhou H, Wu X, Tian J, Zeng J, Yan L, Duan C, Liu H, Li H, Chen K, Hu Z, Ye Z, Xu H*. OncoSplicing: an updated database for clinically relevant alternative splicing in 33 human cancers. Nucleic Acids Res. 2022 Jan 7;50(D1):D1340-D1347. doi: 10.1093/nar/gkab851. PMID: 34554251; PMCID: PMC8728274.

5. Zhang Y, Yan L, Zeng J, Zhou H, Liu H, Yu G, Yao W, Chen K, Ye Z, Xu H*. Pan-cancer analysis of clinical relevance of alternative splicing events in 31 human cancers. Oncogene. 2019 Oct;38(40):6678-6695. Doi: 10.1038/s41388-019-0910-7. Epub 2019 Aug 7. PMID: 31391553.